We have created an explanatory video about SGD-01, a new drug under development by StaGen.
This drug discovery project is led by Naoyuki Kamatani, who previously succeeded in the world’s first gene-based drug discovery. A clinical trial for Parkinson’s disease, supported by AMED, is currently underway at Fujita Health University.
YouTube Post: SGD-01 Overview Video
https://youtu.be/3_E6eslrBuI
For further information, please contact
Mail To : Naoyuki Kamatani, M.D., Ph.D.
or
Mail To : Info StaGen Co., Ltd.
We sincerely thank you for your continued patronage.
We are pleased to announce that our main office will be relocating to the address below.
We kindly ask for your continued support.
Sincerely,
October 1, 2025
New Address: 111-0051
3F T.K. AZUMA Building
4-17-9 Kuramae, Taito-ku, Tokyo
TEL. 03-5835-2137
FAX. 03-5835-2139
Stargen Co., Ltd.
We have posted an introduction video and a presentation material on our groundbreaking new drug, SGD-01, currently under development, presented by our Chairman, Naoyuki Kamatani.
Please be sure to check out the one-page document and YouTube video.
SGD-01 one-page document
https://www.stagen.co.jp/wp-content/uploads/2025/09/SGD-01-one-page-document.pdf
YouTube Post: SGD-01 Overview Video
https://youtu.be/wThQUu6cS_A
The emergency measures after cardiac arrest have the main purpose of preventing neurological damage due to cerebral ischemia. The Keio University Emergency Medicine Department and others reported that adding hydrogen to inhaled gas may be effective in suppressing neurological damage. Statistical analysis of this trial was conducted by StaGen.
Tomoyoshi Tamura, Masaru Suzuki, Koichiro Homma, Motoaki Sano4; HYBRID II Study Group; Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trial.
https://www.thelancet.com/action/showPdf?pii=S2589-5370%2823%2900084-6
A paper co-authored with Prof. Shohei Mitani’s group at Tokyo Women’s Medical University was published. The title is ” Regulation of aging by balancing mitochondrial function and antioxidant levels”.
The paper is on the prevention of aging with XOR inhibitors.
Yoshina S, Izuhara L, Kamatani N, Mitani S. Regulation of aging by balancing mitochondrial function and antioxidant levels. J Physiol Sci. 2022 Nov 15;72(1):28. doi: 10.1186/s12576-022-00853-1.
https://jps.biomedcentral.com/articles/10.1186/s12576-022-00853-1
Content Overview.
Administration of febuxostat (FBX), an XOR inhibitor, to C. elegans showed that FBX protects mitochondria and prevents age-related muscle deterioration. Furthermore, the administration of FBX was shown to increase ATP levels and extend lifespan without overloading the mitochondria. Furthermore, we showed that the combination of FBX and antioxidants increased lifespan even more. The study showed that antioxidant effects and increased ATP levels may lead to anti-aging effects.
StaGen’s comment
Febuxostat administration lowers uric acid and may reduce antioxidant function, but the addition of inosine inhibits uric acid lowering. This paper suggests that an ATP-enhancing drug (a combination of febuxostat and inosine) under development by StaGen may have anti-aging applications.
3rd Kyoto University LifeScience Showcase @ San Diego 2022
Takaba Pharma, a subsidiary of StaGen, applied and was accepted to give a presentation.
As a result of the presentation in the session sponsored by FBRI, Takaha Pharma Co., Ltd. received the FBRI award.
The details of FBRI are as follows
Foundation for Biomedical Research and Innovation at Kobe (FBRI)
President Tasuku Honjo
https://www.fbri-kobe.org/
The video of Takaha Pharma’s presentation is available on Youtube.
The program for the 3rd Kyoto University Life Science Showcase @ San Diego 2022, where Takaha Pharma, a subsidiary of StaGen, is selected to exhibit, has been released.
3rd Kyoto University LifeScience Showcase @ San Diego 2022
The showcase will be held online via Zoom.
March 1, 2022 2- 5:30pm (PST)
March 2, 2022 7-10:30am (JST)
The presentation by Takaha Pharma will be held on March 1 at 3:35pm (PST) or March 2 at 8:35am (JST).
Please register and join us.
In total, administration of [ATP enhancer] to 65 subjects provides support for its safe use in humans, and that latest study in PD patients found that MDS-UPDRS Part III-Motor Score significantly improved after 57 days of treatment. In addition, we were recently granted a patent in the U.S. for our novel method of enhancing cellular ATP and its use as a drug. On top of the previously issued Japanese patent, that patent affords our company protection in two of the world’s most important drug markets. Finally, additional patent applications have recently been published for [ATP enhancer] as an “Anti-aging agent or life extending agent” and as an “Agent to protect mitochondria, ameliorate mitochondrial damage, or improve mitochondrial function”. Those publications allow us to now freely share the underlying data, which we believe represents exciting future growth opportunities.
Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Watanabe H, Hattori T, Kume A, Misu K, Ito T, Koike Y, Johnson TA, Kamitsuji S, Kamatani N, Sobue G. Medicine. 99(35):e21576, August 28, 2020.
Please refer to here
EnePharma will make a company presentation at Biotech Showcase to be held from January 13-15, 2020 at Hilton San Francisco Union Square in San Francisco, CA
Biotech Showcase Event Website
EnePharma will attend JP Morgan Healthcare Conference to be held from January 13-16, 2020 at Westin St. Francis Hotel in San Francisco, CA
JP Morgan Healthcare Conference Event Website
A paper by authors including Johnson and Kamatani of our company was published as a letter in Arthritis and Rheumatology.
Johnson TA, Kuwabara M, Kamatani N. Xanthine oxidase inhibitor withdrawal syndrome? Arthritis Rheumatol. 2019 Aug 5. doi: 10.1002 / art.41066.
PMID:31379099
By analyzing the published data from the CARES study, we found that mortality was higher after discontinuing gout medications allopurinol and febuxostat than during the administration period. For both drugs, the mortality rates were more than 18 times higher within the first month after discontinuation as compared with during the administration period, and the mortality rate gradually declined in about half a year. We considered that both drugs decreased the mortality rate by the ATP enhancement during the administration, but the beneficial effect was abolished by the discontinuation of the drugs. This phenomenon may be called “withdrawal syndrome”. The results of CARES study revealed the mystery that most of the deaths occurred during the off-drug periods, but we think that our present results, for the first time, solved that mystery.